SVB Leerink Maintains Outperform on Certara, Lowers Price Target to $26
SVB Leerink analyst Joy Zhang maintains Certara (NASDAQ:CERT) with a Outperform and lowers the price target from $29 to $26.
Certara: Q2 Earnings Insights
Certara (NASDAQ:CERT) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:15 PM.
Here's what investors need to know about the announcement.
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
SVB Leerink Initiates Coverage On Certara with Outperform Rating, Announces Price Target of $29
SVB Leerink analyst Joy Zhang initiates coverage on Certara (NASDAQ:CERT) with a Outperform rating and announces Price Target of $29.
Barclays Maintains Overweight on Certara, Lowers Price Target to $24
Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Overweight and lowers the price target from $25 to $24.
Piper Sandler Initiates Coverage On Certara with Overweight Rating, Announces Price Target of $28
Piper Sandler analyst Jeff Garro initiates coverage on Certara (NASDAQ:CERT) with a Overweight rating and announces Price Target of $28.
Certara Q1 EPS $0.11 Beats $0.09 Estimate, Sales $81.60M Beat $79.88M Estimate
Certara (NASDAQ:CERT) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.09 by 22.22 percent. This is a 83.33 percent increase over earnings of $0.06 per share from the same
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
